Best-selling Aussie skincare brand Bescher is offering 25 per cent off site-wide until this Sunday
There's a reason skincare fans are racing to restock their Bescher favourites, and right now, the cult-favourite Sea Cucumber Collagen Instant Lift Eye Serum is 25 per cent off until Sunday, 30 June.
Normally $149, the lightweight yet powerful eye serum is down to just $111, and it's gaining attention for delivering what so many products only promise: actual results.
Australian brand Bescher is the first skincare label in the world to use sustainably sourced topical Sea Cucumber Collagen, and it's a game-changer for anyone dealing with tired-looking, crepey, or sagging under-eyes.
Unlike your typical marine or bovine collagen, which often sits on the surface or takes months to show results, Bescher's formula uses an enzymatic process to break down the collagen i nto ultra-small peptides.
We're talking five times smaller than the standard, so they can absorb deeper into the skin and work where it actually matters.
The serum has quickly developed a loyal fan base, with some shoppers calling it an ' instant eye lift in a bottle.'
'My eyes are a problem point for me,' one reviewer shared. 'I have always creased under and around my eyes, and this serum instantly improves the creasing. I definitely felt more confident after applying. I've used it for over a month now and have noticed it has longer-lasting results too. Which I'm super happy about.'
Another said, ' Beautiful eye cream that softens the lines under my eyes. I have quite dark under-eye circles, and I haven't noticed much difference after a couple of months, but I'll definitely continue using this product as I like how it feels and the lift I see.'
So, what's inside? Sea cucumber collagen is naturally rich in Type I collagen, marine peptides, ceramides, triterpene saponins, and GAGs (glycosaminoglycans), all of which work together to regenerate the skin, calm inflammation and support hydration and elasticity.
These powerful ingredients make it a go-to for mature or sensitive skin, especially for those who haven't had luck with traditional products.
The entire Bescher range is designed for results, with no fillers, no fragrance, and no unnecessary fluff.
Just pure, traceable actives that your skin will actually absorb. And the results speak for themselves.
With a return customer rate of over 85 per cent, well above the skincare industry average, it's clear people are coming back for more.
Alongside the bestselling eye serum, Bescher is also offering 25 per cent off sitewide for a limited time. That includes the cult-favourite Day & Night Pack, which contains the Regeneration Serum and normally retails for $249, now marked down to $186.
Spending more than $200? You'll get a free Regeneration Serum valued at $119. Spend over $300, and you'll also score a free Beauty Puffer Bag valued at $69.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
7NEWS
5 hours ago
- 7NEWS
Best-selling Aussie skincare brand Bescher is offering 25 per cent off site-wide until this Sunday
There's a reason skincare fans are racing to restock their Bescher favourites, and right now, the cult-favourite Sea Cucumber Collagen Instant Lift Eye Serum is 25 per cent off until Sunday, 30 June. Normally $149, the lightweight yet powerful eye serum is down to just $111, and it's gaining attention for delivering what so many products only promise: actual results. Australian brand Bescher is the first skincare label in the world to use sustainably sourced topical Sea Cucumber Collagen, and it's a game-changer for anyone dealing with tired-looking, crepey, or sagging under-eyes. Unlike your typical marine or bovine collagen, which often sits on the surface or takes months to show results, Bescher's formula uses an enzymatic process to break down the collagen i nto ultra-small peptides. We're talking five times smaller than the standard, so they can absorb deeper into the skin and work where it actually matters. The serum has quickly developed a loyal fan base, with some shoppers calling it an ' instant eye lift in a bottle.' 'My eyes are a problem point for me,' one reviewer shared. 'I have always creased under and around my eyes, and this serum instantly improves the creasing. I definitely felt more confident after applying. I've used it for over a month now and have noticed it has longer-lasting results too. Which I'm super happy about.' Another said, ' Beautiful eye cream that softens the lines under my eyes. I have quite dark under-eye circles, and I haven't noticed much difference after a couple of months, but I'll definitely continue using this product as I like how it feels and the lift I see.' So, what's inside? Sea cucumber collagen is naturally rich in Type I collagen, marine peptides, ceramides, triterpene saponins, and GAGs (glycosaminoglycans), all of which work together to regenerate the skin, calm inflammation and support hydration and elasticity. These powerful ingredients make it a go-to for mature or sensitive skin, especially for those who haven't had luck with traditional products. The entire Bescher range is designed for results, with no fillers, no fragrance, and no unnecessary fluff. Just pure, traceable actives that your skin will actually absorb. And the results speak for themselves. With a return customer rate of over 85 per cent, well above the skincare industry average, it's clear people are coming back for more. Alongside the bestselling eye serum, Bescher is also offering 25 per cent off sitewide for a limited time. That includes the cult-favourite Day & Night Pack, which contains the Regeneration Serum and normally retails for $249, now marked down to $186. Spending more than $200? You'll get a free Regeneration Serum valued at $119. Spend over $300, and you'll also score a free Beauty Puffer Bag valued at $69.
9 News
6 hours ago
- 9 News
'Waste of money': Aussie influencers enlisted for anti-vaping campaign
Your web browser is no longer supported. To improve your experience update it here The federal government has launched an anti-vaping campaign using popular online influencers to educate young people on the dangers of nicotine addiction. Six high-profile Australians, including a singer, a two-time Paralympian, and a TikTok star, have been enlisted to clear up misinformation and change the narrative on vaping. Among them are Paralympic swimmer Col Pearse, TikTok star Veronia B, known online as Aunty Salma, Australian singer Cxloe and content creator Tedsthetics. The results of the research show why Australia's new vaping laws need to be strictly enforced, University of Sydney Associate Professor Becky Freeman says. (iStock) Research found these high-profile Australians are particularly popular with young people aged between 14 and 20, the federal government said in a statement. Vaping and the use of e-cigarettes is the most common among young people aged between 18 and 24 in Australia, according to the Australian Institute of Health and Welfare. The latest campaign comes after Cancer Council research found government education targeting vaping has contributed to it becoming less "socially acceptable". In one video shared by Veronica B in character as Aunty Salma, she pretended to be an older relative asking a family member why they vape. "What are the pros of vaping? Zero, minus one even," she said in the footage. "The risks of vaping… coughing, breathing problems, nicotine dependence, waste of money and it can affect your brain development." Veronica B AKA Aunty Salma shared a video on the negative impacts of vaping. (TikTok/@yourauntysalma) Two-time Paralympian Pearse shared a video with a more serious note, discussing how vaping can impact your performance as an athlete. He also urged young people to avoid being peer-pressured into trying vaping. "It can be hard to say no at first, but back yourself and your friends are there to help and support you along the journey," he said. "You might even help them say no, too." Paralympic swimmer Col Pearse said vaping impacts your performance as an athlete. (TikTok/@Col_Pearse) Each video asks viewers to download the federal government's My QuitBuddy app, which provides tips and information about staying smoke and vape-free. The Australian government said the influencers have already generated a combined eight million views and 650,000 likes during the first phase of the education campaign. "There is an enormous amount of misinformation and online advertising designed to lure teenagers into vaping," Health Minister Mark Butler said. "Together with the Albanese government's world-leading vaping reforms, education is a key step to stopping Big Tobacco companies from luring a new generation into nicotine dependency. "It's pretty clear that teenagers don't watch TV or listen to health ministers, much as I might like them to, which is why we've partnered with influencers that young people listen to: from comedians, to sport stars and gamers, and everyone in between." Australia smoking health government national CONTACT US
The Advertiser
a day ago
- The Advertiser
'Game changer' diabetes pill a step closer after trials
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
